Table 1.

Selected Sample Means or Percentages for Patients Starting Sulfonylureas (SU) or Thiazolidinediones (TZD) as Second Agent and Patients Assigned to Above‐ and Below‐Median SU‐Prescribing Providers

Demographics	Individual Treatment		Provider SU Prescribing
	Start SU (n = 73,726)	Start TZD (n = 7,210)	Top 50% SUa (n = 40,483)	Bottom 50% SUa (n = 40,453)
Age (years), mean	69.1b	70.1	69.2	69.2
Male	98	98	98	98
White	88	89	90	87
Diabetes management
HbA1c ≥9	9	5	8	8
Retinopathy complications	14	16	14	14
Nephropathy complications	10	12	10	10
Neuropathy complications	19	22	20	19
Cerebrovascular complications	13	14	13	13
Cardiovascular complications (some)	24	28	25	25
Cardiovascular complications (severe)	26	23	25	25
Peripheral vascular complications	14	16	14	14
Metabolic complications	1	1	1	1
Cardiovascular comorbidities
BMI obese	41	39	41	41
Congestive heart failure	13	12	13	13
Cardiac arrhythmias	21	21	21	21
Valvular disease	10	11	9	10
Hypertension	84	84	84	84
Pulmonary circulatory disorder	1	1	1	1
Chronic pulmonary disease	23	21	24	23
Provider process quality variables
Provider % HbA1c >9 in baseline period, mean	10	10	10	10
Provider BP % >140 or >90 in baseline period, mean	41	42	41	41
Provider LDL % >100 in baseline period, mean	38	40	38	38
Outcomes
ACSC hospitalization	18	13	18	17
All‐cause mortality	10	7	10	9
Stroke or AMI	5	4	5	5

^aThese two columns show descriptive statistics of patients assigned to providers who prescribe SU below and above the sample median.

^bFor ease of presentation, percentages are presented unless otherwise noted.

Source. Excerpted from Prentice et al. (2014, table 2).